EGFR and cancer: EGFR‐mutant NSCLC was analyzed using the MSK‐IMPACT assay, a clinical test that detects mutations, copy‐number alterations, and select fusions involving 341 (version 1), 410 (version 2), or 468 (version 3) cancer‐associated genes [74].